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Psychiatric disorders are often associated with metabolic and hormonal alterations, includ-
ing obesity, diabetes, metabolic syndrome as well as modifications in several biological
rhythms including appetite, stress, sleep–wake cycles, and secretion of their correspond-
ing endocrine regulators. Among the gastrointestinal hormones that regulate appetite and
adapt the metabolism in response to nutritional, hedonic, and emotional dysfunctions,
at the interface between endocrine, metabolic, and psychiatric disorders, ghrelin plays a
unique role as the only one increasing appetite.The secretion of ghrelin is altered in several
psychiatric disorders (anorexia, schizophrenia) as well as in metabolic disorders (obesity)
and in animal models in response to emotional triggers (psychological stress . . .) but the
relationship between these modifications and the physiopathology of psychiatric disorders
remains unclear. Recently, a large literature showed that this key metabolic/endocrine reg-
ulator is involved in stress and reward-oriented behaviors and regulates anxiety and mood.
In addition, preproghrelin is a complex prohormone but the roles of the other ghrelin-
derived peptides, thought to act as functional ghrelin antagonists, are largely unknown.
Altered ghrelin secretion and/or signaling in psychiatric diseases are thought to partici-
pate in altered appetite, hedonic response and reward. Whether this can contribute to the
mechanism responsible for the development of the disease or can help to minimize some
symptoms associated with these psychiatric disorders is discussed in the present review.
We will thus describe (1) the biological actions of ghrelin and ghrelin-derived peptides on
food and drugs reward, anxiety and depression, and the physiological consequences of
ghrelin invalidation on these parameters, (2) how ghrelin and ghrelin-derived peptides are
regulated in animal models of psychiatric diseases and in human psychiatric disorders in
relation with the GH axis.
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INTRODUCTION
Psychiatric disorders are often associated with metabolic and
hormonal alterations, including obesity, diabetes, metabolic syn-
drome as well as modifications in several biological rhythms
including appetite, stress, sleep–wake cycles, and secretion of their
corresponding endocrine regulators.
At the interface between endocrine, metabolic, and psychiatric
disorders, ghrelin plays a unique role as the only one increas-
ing appetite. Ghrelin was initially identified as a gastrointestinal
peptide originating from the stomach (1, 2) and as an endoge-
nous ligand for the GH secretagogue receptor (GHS-R1a), the only
ghrelin receptor identified so far. In addition to its primary effect
as a GH secretagogue, ghrelin modulates many other neuroen-
docrine and metabolic functions: it is a powerful orexigenic and
adipogenic peptide and a long-term regulator of energy homeosta-
sis (3, 4). The actions of ghrelin on GH secretion and food intake
require the addition of an eight-carbon fatty acid that is attached
on a serine in position 3 by the enzyme ghrelin-O-acyltransferase
(GOAT) (5, 6) and are exclusively mediated through the GHS-
R1a. In addition, acyl ghrelin is processed from a 117 amino-acid
prohormone that is unique in that it encodes other proghrelin-
derived peptides with structural and functional heterogeneity. A
naturally occurring molecule encoded by the same prohormone
is desacyl ghrelin, which is the most abundant form in plasma (7)
and initially thought to be an inactive peptide resulting from dea-
cylation of ghrelin in tissues and blood (8). Another bioactive 23
amino-acid peptide is also derived from the same precursor and
was originally proposed as the endogenous ligand for the GPR-39
(9). Although non-endocrine biological activities, such as regula-
tion of glucose or lipid metabolism have been attributed to desacyl
ghrelin or obestatin through receptors that still need to be charac-
terized (10–12), some studies suggest that these derived peptides
also antagonize the effects of acylated ghrelin on food intake and
GH secretion (13, 14) (Figure 1).
The GHS-R1a is highly expressed in the hypothalamus, a region
that controls neuroendocrine functions such as GH secretion,
stress, and appetite, in the dorsal vagal complex that receives inputs
from gut vagal afferents and also in the mesolimbic dopaminergic
system of the ventral tegmental area (VTA) involved in addiction
and reward (15, 16). Consistently, a recent literature shows that
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FIGURE 1 | Physiological effects of the different preproghrelin-derived
peptides on GH secretion, adiposity, food reward, drugs reward, and
anxiety/depression. Preproghrelin is a unique prohormone as it encodes
several preproghrelin-derived peptides with structural and functional
heterogeneity. Whereas the contribution of acyl ghrelin, which binds to the
GHS-R1a, has been well explored, the roles of the other variants, desacyl
ghrelin, and obestatin, through receptors that still need to be identified, in
these regulations need to be clarified.
ghrelin is involved in stress and reward-oriented behaviors and
regulates anxiety and mood. Thus, ghrelin is thought to adapt
metabolism in response to emotional dysfunctions. Consistent
with such hypothesis, the secretion of the gastrointestinal hor-
mone and its derived peptides is altered in several psychiatric dis-
orders (anorexia, schizophrenia) as well as in metabolic disorders
(obesity) and in animal models in response to emotional triggers
(such as psychological stress) but the relationship between these
modifications and the physiopathology of psychiatric disorders
remains unclear, especially since contradictory results arise from
the literature. Interestingly, although the prevalence of most psy-
chiatric disorders is not higher in obese individuals, the incidence
of depression and anxiety is increased in this pathology (17).
The focus of this article is to review recent data concerning (1)
the biological actions of ghrelin and ghrelin-derived peptides on
food and drugs reward, anxiety, and depression by exploring phar-
macological actions of the peptides in both rodents and humans
and consequences of genetic or pharmacological blockade of the
ghrelin/GHS-R system on these parameters, and (2) how ghrelin
and ghrelin-derived peptides are regulated in human psychiatric
disorders and animal models of psychiatric diseases such as eating
disorders, anxio-depressive disorders, addiction to alcohol, and
drugs of abuse. The link between ghrelin-derived peptides, GH
axis, and psychiatric disorders will also be discussed.
PREPROGHRELIN-DERIVED PEPTIDES IN EATING DISORDERS
PREPROGHRELIN-DERIVED PEPTIDES AND FOOD REWARD
Many psychiatric disorders are associated with an alteration in
reward-related behaviors linked to the consumption of either
natural reward (food) or drugs of abuse (alcohol, cocaine, nico-
tine, . . .). Both behaviors involve the meso-cortico-limbic system,
including a dopaminergic projection from the VTA to the nucleus
accumbens (NAcc).
Pharmacological actions of ghrelin in animals and humans
A significant number of studies suggest that ghrelin acts directly on
the VTA to increase preference for and motivation to obtain highly
palatable food but no data are available on the actions of the other
ghrelin-derived peptides (Figure 1). In animal models, motiva-
tion to obtain rewarding food (like sucrose) is tested in an operant
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system by measuring lever pressing or nose poking in a progres-
sive ratio paradigm. In such behavioral tests, either intraperitoneal
(i.p), intracerebroventricular (i.c.v) or intra-VTA but not intra-
NAcc ghrelin administration induces motivation for palatable
food by increasing operant lever pressing for sucrose pellets or
for 5% sucrose solution in rats (18–20). Similarly, reinforcement in
satiated rats and motivation for highly palatable food even in food-
restricted animals are increased after intra-VTA chronic ghrelin
infusion (21). Interestingly, this operant response to sucrose pel-
lets following acute intra-VTA ghrelin is prevented by forebrain
dopamine depletion (6-OHDA) (22). In addition, ghrelin-induced
increases in lever presses for a 5% sucrose solution is inhibited by
pre-treatment with the D1-R antagonist, SCH-23390, but not D2-
R antagonist, indicating that ghrelin-induced motivation for food
is mediated via D1-R dependent mechanism. However, the signif-
icant increase for food motivation/reward behavior observed after
ghrelin injection in the VTA is abolished by a pre-treatment with
D1- or D2-receptor antagonist, injected in the NAcc, a main target
of VTA dopaminergic neurons (23).
Ghrelin can also modify food preference, that can be measured
in rodents by a free choice feeding paradigm, where animals are
given a free choice of either chow or highly palatable food. Indeed,
acute bilateral intra-VTA injection of ghrelin in rats increases
consumption of rewarding food (peanut butter) but not stan-
dard chow and i.c.v ghrelin-induced motivation for this rewarding
food is reduced in VTA-lesioned animals (24). Furthermore, in
a two-bottle open access paradigm, i.c.v ghrelin injections in
rats increases consumption of a 5% sucrose solution and this
is prevented by i.p administration of 18-methoxycoronaridine, a
selective antagonist of α3β4 nicotinic receptors, known to reduce
operant response to sucrose (25). However, whether the palata-
bility or the energetic value of energy-rich food is increased by
ghrelin is still unresolved. In a single bottle test, mice injected
i.p with ghrelin show a significant increase in saccharin intake,
in the presence or in the absence of regular food. In addition,
in a free-choice preference test, preference for the non-nutritive
saccharin-flavored jelly is enhanced by i.p ghrelin injection in mice,
demonstrating that ghrelin can augment the overconsumption of a
sweet palatable non-nutritive solution, even when presented with-
out any source of calories (26). However, when rats are given the
choice between a palatable yet low-calorie sucrose solution or a
calorically dense chow, i.c.v or intra-PVN ghrelin administration
results in an increased intake of chow but not sucrose, suggesting
that the primary effect of ghrelin is to stimulate food to satisfy
energy needs (27).
Hedonic and rewarding effects of ghrelin are also observed in
humans. Indeed, ghrelin administered intravenously to healthy
volunteers during fMRI increases the neural response to high-
energy- and low-energy-food pictures evaluation task in brain
regions involved in reward processing and hedonic feeding,
including amygdala, orbitofrontal cortex, anterior insula, striatum
and/or hippocampus (28, 29), and ghrelin effects in the amygdala
are correlated with self-rated hunger score (28).
Genetic or pharmacological blockade of the ghrelin/GHS-R pathway
Suppressed intake of rewarding food in a free-choice food para-
digm, lack of cue-potentiated feeding and suppressed motivation
for food in an operant responding model in ghsr−/− mice support
a role of the endogenous peptide in hedonic eating [for review, see
Ref. (30)]. Attenuated motivation for food in an operant respond-
ing model and decreased hedonic feeding response for a palatable
high-fat dessert has also been described in mice invalidated for
GOAT, the enzyme that acylates ghrelin, suggesting that a specific
role for acyl ghrelin in this response (31).
REGULATION OF PREPROGHRELIN-DERIVED PEPTIDES IN ANIMAL AND
HUMAN PATHOPHYSIOLOGY
Animal pathophysiology
In obesity, changes in food intake and reward-associated behaviors
can be observed, often accompanied by alterations in eating pat-
terns and increased intake of foods with high fat and sugar content
[for review, see Ref. (32)]. Studies in animal models evidenced
a dysregulation of the ghrelinergic pathway in obesity. Indeed,
the long-term exposure to high-fat diet in the diet-induced obese
mouse model leads to lower plasma acyl ghrelin (AG) and total
ghrelin (TG) levels (Table 1), reduced hypothalamic GHS-R1a
expression and suppressed feeding response to ghrelin injections
(33, 34), indicating central ghrelin resistance. Interestingly, the
modulatory action of ghrelin on reward on a progressive ratio
paradigm is blunted in C57BL/6 mice with diet-induced obesity
(35), supporting a dysfunction of the reward system and ghrelin
resistance at the level of the reward circuit as well in obesity.
Human pathophysiology
Dysregulation of the ghrelinergic system is also observed in human
obesity [for review, see Ref. (43)] in relation with the alteration in
the reward system (44) (Table 2). In most obese syndromes, low
plasma ghrelin levels is due to a reduction in the desacyl form
of ghrelin whereas acyl ghrelin is either increased, decreased or
unchanged (45–47) (Figure 2). In contrast, in Prader–Willi syn-
drome, a rare genetic disorder characterized by multiple symptoms
including severe binge-eating, growth retardation as well as learn-
ing disabilities, anxiety and depression, hyperghrelinemia corre-
lates positively with hyperphagia (48, 49) and is mostly due to an
increase in acyl ghrelin levels whereas desacyl ghrelin and obestatin
are unchanged (50, 51). Although the origin of these elevated ghre-
lin levels remain unclear, it could result from undernutrition due
to a failure to thrive during infancy.
Anorexia nervosa is a major cause of undernutrition in young
women. In most of the studies, plasma acyl ghrelin and obestatin
levels are elevated in anorexic patients with a pure restrictive-
type (AN-R) compared to control or obese subjects (52–54, 87)
and an inverse correlation between acyl ghrelin or obestatin and
body mass index (BMI) is found (52). In contrast to AN-R, in
patients with binge-purging (AN-BP), acyl ghrelin is increased and
obestatin levels reduced or unchanged (53, 54), suggesting differ-
ent abilities to adapt to starvation in AN-R and AN-BP despite
similar BMI (Table 2). Inability of ghrelin to induce appetite
during intravenous infusion may suggest some resistance to the
orexigenic peptide in AN-R patients (55). However, pharmaco-
logical effects of ghrelin in AN have not been conclusive yet as
some studies also reported increased hunger sensations after ghre-
lin treatment (56, 57). Data should be interpreted with caution
due to the small number of patients and the difficulty to evaluate
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Table 1 | Regulation of plasma ghrelin concentrations in different mouse models, nutritional status, and experimental conditions.
Type of study Reference Sex Animal model or strain Experimental conditions/
stimulus
Nutritional status Ghrelin secretion
E
at
in
g
d
is
o
rd
er
s/
o
b
es
it
y
(33) M Diet-induced obese C57BL/6
mice
12 weeks on HFD NA ↘ AG and TG in DIO mice
Hypothalamic ghrelin
resistance
(34) M Diet-induced obese C57BL/6
mice
12 weeks on HFD
response to fasting
20 h Fasting ↗ AG in response to fasting
in control and DIO mice
(35) M Diet-induced obese C57BL/6
mice
13 weeks on HFD
response to sucrose
reward
Free access to food Resistance to ghrelin-induced
sucrose reward
A
lc
o
h
o
l a
d
d
ic
ti
o
n
(36) M Wistar, Wistar high preferring
(WHP), Wistar low preferring
(WLP)
Naïve (no alcohol) 12 h fasting ↘ AG and TG in WHP
compared to WLP and Wistar
ethanol-naïve rats
(36) M Wistar, Wistar low preferring
(WLP), Wistar high preferring
(WHP) ethanol naive rat
Acute ip ethanol injection Free access to food ↘ AG and TG in Wistar and
WLP rats
(36) M Wistar alcohol-preferring (PR),
Wistar non-preferring (NP),
Wistar high preferring (WHP),
Wistar low preferring (WLP)
Chronic alcohol
consumption
12 h Fasting ↘↘ AG and TG in PR and
WHP rats
↘ AG and TG in NP and WLP
rats
(37) M Voluntary chronic alcohol
consumption in high-alcohol
(alko, alcohol: AA) and
low-alcohol (alko, non-alcohol:
ANA) consuming rats
Continuous then limited
access to increasing
alcohol concentrations in a
two-bottle-choice drinking
paradigm for 14 weeks
Free access to food ↘TG in AA rats
↘↘TG in ANA rats
(38) M Voluntary chronic alcohol
consumption in Wistar rats
Access to 20% alcohol in a
two-bottle-choice drinking
paradigm during 10 months
Free access to food Plasma ghrelin not assayed
Negative correlation between
GHS-R expression in the VTA
and alcohol intake
D
ru
g
ad
d
ic
ti
o
n (39) M Drug self-administration in
Lister hooded rats
Trained to self-administer
cocaine iv
Restricted diet regime Positive correlation between
plasma ghrelin and
cocaine-seeking behavior
S
tr
es
s/
an
xi
et
y/
d
ep
re
ss
io
n
(40) NA Caloric restriction 60% Caloric restriction
during 10 days
60% Caloric restriction ↗ GA
(40) M Chronic social defeat stress
(CSDS)
10 days of CSDS Free access to food ↗ GA associated with
increased caloric intake and
weight gain
(41) M Chronic social defeat stress
(CSDS)
10 days of CSDS Free access to food ↗ GA and = GNA in both WT
and KO
Attenuated weight gain and
feeding in GHS-R compared
to WT
(42) M High-anxiety Wistar Kyoto and
low-anxiety SD rats
Unstressed Free access to food ↘TG in high-anxiety
compared to low-anxiety rats
(42) F High-anxiety Wistar Kyoto
(WKY) and low-anxiety SD
(SPD) rats
Acute exposure to water
avoidance
Free access to food ↗TG in WKY
↗↗TG in SPD
M, male; F, female; NA, not available; TG, total ghrelin; AG, acyl ghrelin; Ghrelin, no information on isoform measured.
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Table 2 | Regulation of plasma ghrelin/obestatin concentrations in different human pathologies, health and nutritional status, and experimental
conditions.
Type of
study
Reference Sex Subjects and health status Experimental conditions/
stimulus
Nutritional status/time
of sampling
Ghrelin/obestatin secretion
E
at
in
g
d
is
o
rd
er
s/
o
b
es
it
y
(52) 32 F 10 Obese (OB)
11 Anorexia nervosa (AN)
11 Healthy controls (HC)
Basal conditions Morning after overnight
fast
↘ G,↘ AG,↘ obestatin (OB)
↗ AG,↘ DAG,↗ obestatin
(AN)
(53) 41 F 10 Constitutional thinness
(CT) 15 AN-R
7 AN-R recovered (PRAN)
9 HC
Basal conditions Morning after overnight
fast
Circadian pattern (every
4 h)
↗ AG and TG,↗ obestatin
(AN)=AG,=obestatin (CT)
(54) 57 F 22 AN-R
10 AN-BP
16 AN-BN
9 HC
Basal conditions Morning after overnight
fast
Circadian pattern
↗ AG and TG,↗ obestatin
(AN-R)
↘ AG and TG,↘ obestatin
(AN-BP)
↘ AG and TG,↘ obestatin
(BN)
(55) 25 F 9 AN, 6 AN recovered, 10 CT Basal conditions Morning after overnight
fast
↗TG (AN)
(55) 25 F 9 AN
6 AN recovered
10 CT
Ghrelin infusion
(5 pmol/kg×min) during
300 min
Morning after overnight
fast
↘ GH response to ghrelin
= Feeding response to ghrelin
(56) 16 F 9 AN-R
7 HC
Basal conditions Morning after overnight
fast
↗TG (AN)
(56) 16 F 9 AN-R
7 HC
Acute ghrelin
administration (1.0µg/kg)
Morning after overnight
fast
↘ GH response to ghrelin
= Glucose response to
ghrelin
(57) 5 F 5 AN-R Ghrelin infusion for
24 days: 3µg/kg for 5 min
during 14 days before
breakfast and dinner
Morning after overnight
fasting
↗ Hunger sensation
evaluated as VAS score
(45) M
F
Normal weight
Obese, no metabolic
syndrome (no-MS)
Obese, metabolic syndrome
(MS)
Basal conditions Morning after overnight
fast
↘TG and DAG, = AG (MS)
↘TG and↗ AG (non-MS)
(46) 34 M Normal weight (17 M)
Overweight (17 M)
Basal conditions Fasting ↘TG and DAG (in OW)
= AG (in OW)
(47) 101 M
79 F
Normal weight (31 M, 34 F)
Obese, no metabolic
syndrome (no-MS) (40 M,
20 F)
Obese, metabolic syndrome
(MS) (30 M, 25 F)
Basal conditions Overnight fasting ↗ AG and↘ DAG (non-MS)
↗↗ AG and↘↘ DAG (MS)
(48) 21 M
27 F
Prader–Willi syndrome (PWS)
(10 M, 8 F)
Obese (4 M, 10 F)
Lean (7 M, 9 F)
Basal conditions Overnight fasting ↗TG (in PWS)
(Continued)
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Table 2 | Continued
Type of
study
Reference Sex Subjects and health status Experimental conditions/
stimulus
Nutritional status/time
of sampling
Ghrelin/obestatin secretion
(49) M
F
Prader–Willi syndrome (PWS)
obese controls
Basal conditions Fasting ↗TG (in PWS)
(50) 21 Prader–Willi syndrome (PWS)
(11)
Obese control children (10)
Identical BMI
Basal conditions Fasting ↗ AG
= DAG
(51) Prader–Willi syndrome (PWS)
(15)
Obese control children (18)
Identical BMI
Basal conditions NA ↗ AG and TG
= Obestatin
A
lc
o
h
o
l a
d
d
ic
ti
o
n
(58) 4 M
4 F
Healthy subjects
Non-obese (moderate social
drinkers)
Acute oral (ethanol versus
drinking water)
Morning ↘TG
(59) 6 M
6 F
Healthy subjects
Normal BMI (moderate social
drinkers)
Acute oral (ethanol versus
drinking water)
Overnight fasting
before and after ethanol
↘ AG and TG
(60) 9 M Healthy subjects
Normal BMI
Acute oral (ethanol versus
non-ethanol drink)+ stress
exposure
Early afternoon before
and after ethanol
↘TG
(61) 5 M
5 F
Healthy subjects
Non-obese (moderate social
drinkers)
Acute oral (ethanol versus
drinking water)
Morning fed before and
after ethanol
↘TG
= Obestatin
(62) 22 M
22 F
Healthy subjects
Normal BMI (moderate social
drinkers)
Acute intravenous (ethanol
versus saline)
Morning fed ↘TG,=obestatin
No gender effect
(63) 20 M Healthy subjects: lean (11) or
overweight (9)
Moderate alcohol during
3 weeks
Overnight fasting ↗ Ghrelin
(64, 65) 142 Healthy control (24)
Alcohol-dependent (early
abstainers, 21)
Alcohol-dependent (active
drinkers, 97)
Normal BMI
Chronic alcoholism Overnight fasting ↗ Ghrelin in alcoholic
compared to HC
↗ Ghrelin in early abstainers
compared to active drinkers
(66) 44
(M+F)
Healthy control (20) versus
alcohol-dependent (24)
Non-obese
Chronic alcoholism Overnight fasting ↘ Ghrelin
(67) 30 M Healthy control (15 M) versus
alcohol-dependent (15 M)
Non-obese
Chronic alcoholism Overnight fasting ↘ Ghrelin
Positive correlation between
ghrelin levels and alcohol
craving
(68) 115 M
39 F
Healthy control (12 F+33 M)
versus alcohol-dependent (27
F+82 H)
Normal BMI
Chronic alcoholism NA ↗ Ghrelin (females)
= Ghrelin (males)
Positive association between
ghrelin and alcohol craving
(Continued)
Frontiers in Endocrinology | Neuroendocrine Science October 2014 | Volume 5 | Article 163 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Labarthe et al. Ghrelin and psychiatric disorders
Table 2 | Continued
Type of
study
Reference Sex Subjects and health status Experimental conditions/
stimulus
Nutritional status/time
of sampling
Ghrelin/obestatin secretion
(69) 97 M Healthy control (50 M) versus
alcohol-dependent abstainers
(47 M)
Normal BMI
>30 days of abstinence Overnight fasting ↗ Ghrelin
Positive correlation between
ghrelin and duration of
abstinence
(70) 111 M Healthy control (50 M) versus
alcohol-dependent abstainers
(61 M)
14 days of abstinence Overnight fasting ↗ AG and =TG
Positive association between
AG and alcohol craving
(71) 64 M Alcohol-dependent abstainers
(64 M) classified in normal
glucose tolerance (NGT),
pre-diabetes (pre-DM) and
diabetes (DM)
Normal BMI
>30 days of abstinence
with rehabilitation
treatment
Overnight fasting ↗ Ghrelin in NGT
↗↗ Ghrelin in pre-DM and
DM
D
r u
g
ad
d
ic
ti
o
n
(72) 11 Heavy smokers Acute 24 h nicotine
withdrawal
Fed a light meal 2 h
before
No association between TG
and craving or withdrawal
symptoms
(73) 123 M
143 F
Young adults
Normal BMI
Intrauterine exposure to
prenatal smoke
Smoking and food
ad libitum
↗TG
(74) 54 M Smokers (31 M) and
non-smokers (23 M)
Slightly overweight
Chronic smoking Overnight fasting and
abstinence from
smoking
=TG
(74) 54 M Smokers (31 M) and
non-smokers (23 M)
Slightly overweight
Acute smoking (2
cigarettes)
Overnight fasting and
abstinence from
smoking
=TG (smokers)
↘TG (non-smokers)
(75) 24 M
26 F
Healthy non-smokers
Normal BMI
Nicotine administration Overnight fasting = DAG
(60) 9 M Healthy subjects Psychological
stress=public speaking
stressor
NA =TG
S
tr
es
s/
an
xi
et
y/
d
ep
re
ss
io
n
(76) 8 M
16 F
Normal weight (8)
Obese (8)
Binge-eating (8)
Psychological
stress= standardized trial
social stress test
(TSST)=public speaking
Morning after light
breakfast
=TG after psychological
stress Positive correlation
between the change in TG
and the change in cortisol
(77) 103 F Healthy subjects Stress=public speaking Food provided ↘ AG in emotional eaters
↗ AG in women anticipating
the stressor compared to
those not subjected to the
stressor
↘ AG in non-emotional eaters
following food consumption
= AG in non-emotional eaters
following food consumption
(78) 68 M
61 F
Major-depressive disorder
(MDD) (44 M, 39 F)
Healthy subjects (24 M, 22 F)
MDD slightly overweight
Basal conditions Overnight fast =TG in MDD
Positive correlation between
ghrelin and eating behavior
scales TFEQ
(Continued)
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Table 2 | Continued
Type of
study
Reference Sex Subjects and health status Experimental conditions/
stimulus
Nutritional status/time
of sampling
Ghrelin/obestatin secretion
S
tr
es
s/
an
xi
et
y/
d
ep
re
ss
io
n
(79) 18 M
22 F
MDD patients (9 M, 11 F)
Healthy subjects (9 M, 11 F)
Normal BMI
Basal conditions Fed
Overnight sampling
=TG in MDD
(80) M+F MDD patients (9 M, 6 F)
Healthy subjects (16)
Basal conditions = AG or TG in MDD
(81) 48 M+F MDD patients (24)
Healthy subjects (24)
Basal conditions Overnight fasting = AG in MDD
Positive correlation between
AG and the severity of
reduced appetite in MMD
(82) 64 F Anorexic patients (15)
Normal weight (32)
Overweight (17)
Basal conditions Overnight fasting No relationship between TG
and symptoms of depression
or anxiety
(83) 245
M+F
MDD or panic disorders
Treatment responders (89)
Treatment non-responders
(59)
Healthy subjects (97)
Basal conditions Early afternoon
No eating 60 min before
↗ AG in treatment-resistant
patients
(84) 12 M
12 F
MDD patients (24)
Healthy subjects (22)
Basal conditions
citalopram treatment
(3 months)
Overnight fasting ↘ AG and TG in MDD
↘ AG and TG after treatment
(85) 40 M MDD lean patients (40 M) Basal conditions
maprotiline treatment
(30 days)
Overnight fasting ↗TG and weight gain after
treatment
(86) M+F Major-depressive episode
(MDE, 16)
Bipolar disorder manic
episode (BD-me, 12)
Healthy subjects (25)
Electroconvulsive therapy
(ECT)
Overnight fasting ↘ AG after treatment in all
subgroups but BMI
unchanged
M, male; F, female; BMI, body mass index; OB, obese; AN-R, anorexia nervosa restrictive-type; AN-BN, anorexia nervosa with episodes of bulimia; AN-BP, anorexia
nervosa with episodes of binge-purging; HC, healthy control; CT, constitutional thinness; MDD, major-depressive disorder; NA, not available; AG, acyl ghrelin; DAG,
desacyl ghrelin; TG, total ghrelin; Ghrelin, either TG or AG (?).
the degree of hunger in this pathology. Other factors that may
counterbalance hyperghrelinemia should be taken into account.
Interestingly, it has been hypothesized that higher obestatin lev-
els in the restrictive type may also contribute to the reduced
hunger and/or reduced motivation to eat in this pathology (53,
54) (Figure 2).
Alterations in the serotonergic/dopaminergic signaling are
described in AN patients (88, 89) and avoidance for food is
positively correlated with the increased striatal D2/D3 receptor
binding. The altered impact of ghrelin on the reward system
could modify the integration of information related to emotional
processes, as suggested by connections between the prefrontal cor-
tex and the NAcc. Interestingly, it has been demonstrated that the
heterodimeric formation of ghrelin receptor and dopamine D2-
receptor is required for the anorexigenic effects of dopamine in
hypothalamic neurons (90). The co-expression of these receptors
in the mesolimbic dopaminergic system may also be important to
modulate motivation and reward.
PREPROGHRELIN-DERIVED PEPTIDES IN ALCOHOL
ADDICTION
PREPROGHRELIN-DERIVED PEPTIDES AND ALCOHOL CONSUMPTION
Several reviews already focused on the role of the ghrelin/GHS-R
signaling in the rewarding properties of alcohol in animal mod-
els or humans (91, 92). A large number of studies demonstrate
that ghrelin is involved in alcohol intake, showing altered plasma
ghrelin levels in alcoholic patients or high-alcohol consuming rat
strains as well as reduced alcohol intake in animal with disrupted
ghrelin signaling. However, very little pharmacological data exist
so far.
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FIGURE 2 | Plasma levels of preproghrelin-derived peptides in
metabolic and psychiatric disorders. In anorexic patients, total ghrelin,
acyl ghrelin, and obestatin are increased in the restrictive type and reduced
in binge-purging. This may represent different abilities to adapt to starvation.
In obesity syndromes, total ghrelin, acyl ghrelin and obestatin are either
found reduced, unchanged, or increased. Discrepancies may be due to the
variety of obesity syndromes (monogenic obesity, nutritionally induced
obesity, presence of a metabolic syndrome, multifactorial disorders such as
the Prader-Willi syndrome). In alcohol-dependent patients, ghrelin is found
either reduced or increased compared to healthy subjects but there might
be differences in gender, body mass index, nutritional/metabolic status
and/or time after alcohol withdrawal from one study to another that can
explain the contradictory results. In major depressive disorders, the majority
of studies report no differences in plasma total or acyl ghrelin levels
compared with healthy controls. Whether ghrelin can contribute to the
degree of food craving, alcohol craving or depression is not clearly
demonstrated as treatments and metabolic modifications can interfere with
the results.
Pharmacological actions of ghrelin in animals and humans
Ghrelin, delivered either peripherally, centrally or directly in spe-
cific brain nuclei, increases reward-relevant behaviors such as alco-
hol consumption (92) (Figure 1). Central ghrelin administrations,
i.c.v or directly in the VTA or laterodorsal tegmental area (LDTg),
increase alcohol intake in a two-bottle (alcohol/water) free-choice
paradigm where access to alcohol was limited to 90 min/day for
2 weeks in C57BL/6 mice, a strain with high-alcohol preference
(93). Pre-clinical models termed “drinking in the dark” (DID) are
developed to examine binge-like ethanol consumption in rodent
populations (94). In this procedure where animals have a 2 h access
to a 20% ethanol solution during the beginning of the dark period,
neither food deprivation nor i.p administration of ghrelin altered
drinking in C57BL/6J mice (95). In humans, intravenous ghre-
lin administration increases alcohol craving in alcohol-dependent
heavy drinkers (96).
Genetic or pharmacological blockade of the ghrelin/GHS-R pathway
Genetic or pharmacological blockade of the GHS-R1a also reveals
the importance of ghrelin signaling in alcohol-related behav-
iors. Pharmacological blockade with GHS-R1a antagonists reduces
voluntary alcohol consumption and preference and suppresses
reward induced by alcohol in both rats and mice [reviewed in
Ref. (91)]. For example, JMV2959, a selective GHS-R1a antago-
nist, impacts both acute and chronic alcohol consumption. Acute
injections of the antagonist reduce the operant self-administration
of alcohol in rats, decreases high-alcohol consumption in two
strains of alcohol-preferring rats, Long–Evans and alko alcohol
(AA) preferring rats (97) as well as alcohol consumption after
several months of exposure to alcohol (38). Chronic administra-
tions of the antagonist decrease alcohol intake without inducing
tolerance or rebound (38). In mice, in a two-bottle choice par-
adigm, the non-selective antagonist [d-Lys3]-GHRP-6 reduces
preference to alcohol (98). In addition, GHS-R1a blockade with
JMV2959 either peripherally or centrally reduces voluntary alco-
hol consumption and preference, alcohol-induced locomotor
stimulation, accumbal DA release, and conditioned-place pref-
erence (CPP) (93, 99). Similarly, when compared to wild-type
mice, ghrelin−/− mice display lower ethanol-induced CPP and
locomotor stimulation and reduced voluntary alcohol consump-
tion and preference in a two-bottle choice test (99). The abil-
ity of alcohol to increase NAcc dopamine release is absent in
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ghrelin−/− mice (100). The rewarding properties of alcohol are
also reduced in the ghsr−/− mice (93). However, Spiegelmer-
neutralization of circulating ghrelin, thereby preventing its access
to the brain, does not attenuate alcohol-induced locomotor activ-
ity, NAcc DA release, and CPP in mice, neither modifies alco-
hol consumption in a two-bottle free-choice paradigm in rats,
suggesting that central rather than peripheral ghrelin signal-
ing is preferentially involved in alcohol consumption (101). In
contrast, Roux-en-Y gastric bypass (RYGB), which reduces cir-
culating ghrelin levels, decreases ethanol intake and the rein-
forcing properties of ethanol in ethanol-preferring rats. In this
model, pharmacological replacement of ghrelin restores drink-
ing behavior (31), suggesting that endogenous circulating ghrelin
is important in alcohol preference. It should also be noted that,
in RYGB rats, a GHS-R1a antagonist, [d-Lys3]-GHRP-6, reduces
operant performance to earn alcohol reward and alcohol con-
sumption, suggesting that increased ghrelin might contribute
to increased alcohol reward in such animals (102). Altogether,
these data suggest that selective blockade of the ghrelin/GHS-R
pathway could be a potential treatment for pathological alcohol
consumption.
REGULATION OF PREPROGHRELIN-DERIVED PEPTIDES IN ANIMAL AND
HUMAN PATHOPHYSIOLOGY
Although ghrelin induces addictive behaviors, including alcohol
consumption in both rodents and humans, an important ques-
tion is whether hyperghrelinemia is associated with addictive
behaviors, such as alcohol drinking. Conflicting data concern-
ing the involvement of ghrelin in the physiopathology of alcohol
dependence have been reported (103, 104).
Animal pathophysiology
In rodents, chronic alcohol consumption leads to reduced total
and acylated ghrelin levels in rats of different strains (PR: Wistar
alcohol preferring, NP: Wistar non-preferring, and WHP: Wis-
tar high preferring) but the lowest ghrelin levels are observed
in PR and WHP strains (Table 1). Furthermore, there is an
inverse relationship between ghrelin levels and alcohol intake
(36). In high-alcohol (AA) consuming rats, reduction in plasma
total ghrelin levels after alcohol exposure during several weeks
is of lower amplitude as compared to low-alcohol (ANA) con-
suming rats (37). Interestingly, GHS-R1a expression in NAcc,
VTA, amygdala, prefrontal cortex, and hippocampus is higher
in AA rats, suggesting that the ghrelin pathway may be involved
in alcohol susceptibility. But, after 10 months of voluntary alco-
hol consumption induced by intermittent access to alcohol in
a two-bottle choice drinking paradigm, GHS-R expression in
the VTA is significantly down-regulated in high- compared to
low-alcohol consuming Wistar rats and a negative correlation
is observed between GHS-R expression in the VTA and alcohol
intake (38).
Human pathophysiology
In healthy humans, acute alcohol consumption induces signifi-
cant declines in total and acylated ghrelin concentrations as early
as 15 min following alcohol ingestion (58–61), whereas obestatin
levels are unchanged (61). Interestingly, fasting-induced increase
in ghrelin levels is also reduced after intravenous alcohol admin-
istration in both males and females (62). In contrast, after moder-
ate alcohol consumption during 3 weeks in healthy men, ghrelin
concentrations are increased but both lean and overweight sub-
jects were included in the analyses and plasma ghrelin levels tended
to be lower in overweight associated with reduced insulin sensi-
tivity (63). Data concerning the effect of chronic alcohol intake
in alcohol-dependent subjects are conflicting. Indeed, alcohol
dependence is associated with either increases or decreases in
plasma ghrelin levels compared to healthy control subjects (65–67)
(Figure 2) but higher ghrelin levels correlate with higher measure-
ments of alcohol craving using the obsessive compulsive drinking
scale (OCDS) (67, 105, 106) (Figure 3). Some difficulties in com-
paring data from the literature are that explorations are sometimes
performed in different genders, various BMI, early abstainers ver-
sus active drinkers and at different times after alcohol withdrawal.
The small number of subjects in some studies is also a factor to
take into account (Table 2). Interestingly, a study comparing both
genders found that ghrelin levels are higher in female alcohol-
dependent patients only when compared to appropriate gender
controls while no differences are found in males (68), suggest-
ing that ghrelin response may be gender dependent. In addition,
among alcohol-dependent subjects, ghrelin levels are higher in
early abstainers compared to active drinkers (65). Although most
hormonal explorations are performed after an overnight fast,
nutritional status at the time of sampling may also contribute
to differences observed. Finally, differences in ghrelin secretion
observed in alcohol-dependent patients from one study to another
may also be a consequence of the loss of metabolic control as alco-
hol intake is compensated by a decrease in non-alcoholic nutrient
intake (66). Consumption of other substances of abuse can also
interfere with plasma ghrelin levels and although smoking is an
exclusion factor in some studies (62), others have to take into
account the smoking status of the participants (70).
Whereas alcohol intake seems to reduce plasma ghrelin lev-
els, alcohol withdrawal induces elevation in plasma concentra-
tions of the hormone. Indeed, fasting plasma ghrelin levels are
higher in alcohol abstainers than in controls and ghrelin lev-
els are positively correlated to the duration of abstinence (64,
69–71). Ghrelin elevation, however, is greater in subjects with pre-
diabetes and diabetes mellitus than in normoglucose-tolerant sub-
jects (71), suggesting that metabolic factors impact the hormone
levels.
Finally, only one study to date reported that a GHSR gene
polymorphism was more frequent in heavy drinkers than in mod-
erate drinkers and abstinents (107), suggesting genetic association
between ghrelin and heavy alcohol consumption.
In conclusion, reduced plasma ghrelin levels with alcohol con-
sumption and elevated levels with abstinence, as well as correlation
between ghrelin and alcohol craving suggest that elevated ghre-
lin might contribute to cravings for alcohol (Figures 2 and 3).
However, plasma concentrations of DAG and obestatin, regarding
alcohol status, are unknown and the contribution of these other
ghrelin-derived peptides in alcohol addiction would need to be
explored as well (Figure 2).
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FIGURE 3 | Proposed model of hedonic/reward response to ghrelin
after chronic stress in relation with anxio-depressive symptoms. During
chronic stress, increased ghrelin secretion has been shown to induce
emotional eating by acting at the level of the hedonic/reward system. As
ghrelin has been shown to have anxiolytic actions in response to stress, this
adaptative response may contribute to control excessive anxiety and
prevent depression. In obesity, lower ability to mobilize ghrelin in response
to stress or central ghrelin resistance at the level of the hedonic/reward
system may explain the inability to cope with anxiety and increased
susceptibility to depression. Reciprocally, depressed subjects have
increased susceptibility to obesity or eating disorders (due to altered
hedonic/reward response). Elevated ghrelin may also contribute to
alcohol/drug craving: higher ghrelin levels correlate with higher
measurements of alcohol craving.
PREPROGHRELIN-DERIVED PEPTIDES IN ADDICTION TO
DRUGS OF ABUSE
PREPROGHRELIN-DERIVED PEPTIDES AND CONSUMPTION OF DRUGS
OF ABUSE
Pharmacological actions of ghrelin in animals and humans
An emerging literature demonstrates that ghrelin modulates
the action of psychostimulants such as nicotine, amphetamine,
cocaine, and heroin but no data is available on the effects of the
other ghrelin-derived peptides (Figure 1). In animal models, these
rewarding properties of drugs of abuse are often measured by loco-
motor stimulation, NAcc dopamine release and/or CPP. Indeed,
systemic ghrelin infusion increases cocaine-induced hyperloco-
motion as well as CPP in rats [reviewed in Ref. (108)]. In addition,
i.c.v infusion of ghrelin induces an increase in heroin reinforce-
ment breakpoint on a progressive ratio schedule when animals
have to work to obtain a reward (109). Bilateral micro-injection
of ghrelin into the NAcc, where cocaine induces locomotor activa-
tion, increases cocaine-induced hyperactivity and these effects are
blocked by a GHS-1a antagonist, [d-Lys3]-GHRP-6, in rats (110).
Finally, ghrelin also amplifies nicotine-induced striatal dopamine
release in this species (111).
In healthy non-smokers, after a caloric load of glucose, nicotine
increases the modulatory effect of ghrelin on food-cue reactiv-
ity, measured by magnetic resonance imaging, in the ventrome-
dial prefrontal cortex (112). No other clinical data are currently
available and observations in rodents will need to be confirmed in
humans.
Genetic or pharmacological blockade of the ghrelin/GHS-R pathway
As for alcohol consumption, GHS-R1a antagonists have been
shown to suppress reward induced by cocaine and amphetamine.
This was partly reviewed previously [reviewed in Ref. (91)] and
recent data corroborate these findings. In rats, inactivation of ghre-
lin signaling by JMV2959 reduces nicotine-induced locomotor
sensitization (108). In mice, the ability of nicotine, amphetamine,
and cocaine to induce hyperlocomotion, to stimulate NAcc DA
release and to condition a place preference is reduced after treat-
ment with the same GHS-R1a antagonist (100, 113). In addition,
in rats, the ability of morphine to induce behavioral stimula-
tion, including stereotyped behavior and DA release in the NAcc
is reduced by JMV2959 injections (114). Genetic ablation of
GHS-R in mice similarly attenuates hyperlocomotion and CPP
induced by nicotine, cocaine, and amphetamine (108). However,
although exogenous ghrelin administration increases heroin self-
reinforcement as described above, central administration of the
GHS-R1a antagonist [d-Lys3]-GHRP-6, has no effect on heroin
self-administration or food-deprivation induced reinstatement
of heroin seeking behavior (109). Whether this lack of effect
is due to the specificity of the antagonist or the nature of the
psychostimulant (i.e., heroin or other) is unknown.
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REGULATION OF PREPROGHRELIN-DERIVED PEPTIDES IN ANIMAL AND
HUMAN PATHOPHYSIOLOGY
A positive correlation between plasma ghrelin levels and cocaine-
seeking behavior is observed in rats trained to self-administer
cocaine i.v (39).
Very little pre-clinical and clinical data are available con-
cerning substance of abuse and ghrelin levels (Table 2). In
humans, circulating total ghrelin levels are not associated with
craving and withdrawal symptoms in heavy smokers suffer-
ing from acute 24 h nicotine withdrawal (72). Young adults
exposed to prenatal smoke have higher plasma total ghrelin
levels (73). No differences in total ghrelin levels are found
between smokers and non-smokers and smoking two ciga-
rettes acutely does not provoke any short-term changes in
total ghrelin levels in smokers but induces a decline in non-
smokers (74). However, nicotine administration in healthy non-
smokers does not alter plasma non-acylated ghrelin levels (75).
Genetic association studies only report variation of the ghre-
lin signaling system in individuals with amphetamine depen-
dence (38).
CENTRAL MECHANISM OF ACTION MEDIATING
REWARD-RELEVANT BEHAVIORS
MESOLIMBIC CHOLINERGIC-DA SYSTEM
All major drugs of abuse acutely activate the mesolimbic dopamine
system. Several lines of evidence converge to show that ghre-
lin activates the cholinergic –dopaminergic reward link, includ-
ing a dopaminergic projection from the VTA to the NAcc to
increase the consumption of rewarding foods and alcohol after
i.v and i.c.v administrations in rodents (91). Ghrelin admin-
istration peripherally or locally into the LDTg concomitantly
increases VTA acetylcholine as well as DA release in rats. In
contrast, a GHS-R1a antagonist blocks this synchronous neuro-
transmitter release induced by peripheral ghrelin. In addition,
local perfusion of a non-selective nicotinic antagonist mecamy-
lamine into the VTA blocks the ability of ghrelin to increase NAcc
dopamine but not VTA acetylcholine (115). The ability of alco-
hol to increase accumbal DA release in wild-type mice is not
observed in ghr−/− mice, suggesting that endogenous ghrelin may
be required for the ability of alcohol to activate the mesolimbic
DA system (116).
The mesolimbic GHS-R also plays an important role in the
response to drugs of abuse. Indeed, JMV2959, a GHS-R1a antag-
onist, reduces morphine-induced DA release in the NAcc and
behavioral stimulation, including stereotyped behavior (114).
Amphetamine- and cocaine-induced locomotor stimulation and
NAcc DA release, as well as the ability of these drugs to condition
a place preference, are reduced in mice treated with JMV2959 in
the mouse (113).
Central pathways involved in increased alcohol or other
drugs consumption potentially involve several other struc-
tures and neurotransmitters, beside dopamine release in the
NAcc. For example, ghrelin-induced locomotor stimulation
is attenuated by VTA administration of AP5, a selective
NMDA receptor antagonist, but not orexin-A antagonist or
peripheral opioid receptor antagonist (naltrexone) in mice
(117).
GLUTAMATERGIC/GABAergic SYSTEM
In central amygdala (CeA) GABAergic neurons, critical in regulat-
ing ethanol consumption and the response to ethanol withdrawal,
ghrelin attenuates ethanol-increased IPSP amplitude and super-
fusion of GHS-R1a antagonists decreases IPSC and mIPSC
frequency and block ghrelin-induced increases in GABAergic
responses (118). Ghrelin regulation of alcohol consumption may
also involve the perioculomotor urocortin neurons (pIIIu) as [d-
Lys3]-GHRP-6 reduces the induction of cFos by i.p ethanol in this
population of neurons but not in the VTA or arcuate nucleus of
the hypothalamus (98).
SEROTONIN SYSTEM
The serotonin (5-HT) system is also involved in the response to
ghrelin. Indeed, acute central ghrelin injections in mice increase
5-HT turnover in the amygdala and 5-HT-R mRNA in the amyg-
dala and dorsal raphe (119). The serotonin system is also regulated
by endogenous ghrelin/GHS-R signaling. Indeed in ghsr−/− mice,
decreased expression of 5-HT-R is observed in the amygdala and
dorsal raphe (119).
PREPROGHRELIN-DERIVED PEPTIDES IN STRESS/ANXIETY/
DEPRESSION
PREPROGHRELIN-DERIVED PEPTIDES AND STRESS-RESPONSE/
ANXIETY/DEPRESSION
Pharmacological actions of ghrelin in animals and humans
Ghrelin is involved in neuroendocrine and behavioral responses
to stress through activation of the HPA axis: peripheral ghrelin
indeed increases hypothalamic CRH mRNA and serum corticos-
terone. In addition, ghrelin-induced anxiogenic effects are inhib-
ited by a CRH receptor antagonist (120). Behavioral responses
include anxiety-like behaviors like exploration in the open field,
elevated plus maze (EPM), light/dark box, and social interactions.
In the mouse,both i.c.v and i.p administration of ghrelin induce
anxiogenic behavior in the EPM test (120). Intracerebroventric-
ular injections or direct injections in specific nuclei, including
the hippocampus, amygdala, dorsal raphe nucleus or in several
hypothalamic nuclei (Arc, PVN, VMH, PFH) induce anxiogenic
responses in the open-field or EPM in both male and ovariec-
tomized female rats (121–125), whereas i.c.v injection of obestatin
elicits an anxiolytic effect in the EPM test (Figure 1) (126).
In rats, chronic i.c.v treatment with ghrelin also reveals an
increase in anxiety- and depression-like behaviors that are associ-
ated with modifications in the expression of key markers involved
in these behavioral changes in the amygdala (127). Interest-
ingly, the anxiogenic actions of ghrelin are inhibited by a CRH
antagonist, suggesting that anxiety response may be relayed by
hyperactivity of the HPA stress axis (120). Electrophysiological
responses to ghrelin challenges in the dorsal raphe, the main region
expressing serotonergic neurons, which are key mediators of emo-
tional reactivity further support a key role of ghrelin in emotional
responses (127).
Despite a large literature supporting a pro-anxiety action
of ghrelin in rodents, contradictory data arise from the effects
of ghrelin on anxiety response (Figure 1): one study demon-
strates that a subcutaneous injection of the 28-AA peptide pro-
duces anxiolytic- and antidepressant-like responses in the EPM
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and forced-swim test in mice (40) while in another study in
food-deprived rats during 1 h between ghrelin injection and test-
ing, a decrease in anxiety-like behavior was observed after intra-
amygdala injections (122). This discrepancy needs to be clarified
and may reflect differences in contextual environment during
the testing period (i.e., situation where stress in present or not,
see below in the next paragraph differential response in basal
conditions or in response to stress).
So far, human data on the effects of ghrelin are missing and
do not corroborate observations in rodents. One study demon-
strates that, in male and female patients with mood depressive
disorders (MDD), ghrelin administration (50µg between 11 p.m.
and 1 a.m.) induces transient GH and cortisol secretion, increases
the time of sleeping in males only but has no significant effect
on depressive symptoms (128). Ghrelin affects the sleep/wake pat-
tern in healthy subjects and may have also the same effect on MDD
patients but it seems independent of the etiology of the depression.
Genetic or pharmacological blockade of the ghrelin/GHS-R pathway
Data are currently missing concerning the effects of GHS-R1a
pharmacological blockade on anxiety- and depression-like behav-
iors but exploration of knock-out models give some insights about
endogenous ghrelin function. ghsr−/− mice have reduced latency
to leave center in the open-field test, suggesting increased anxiety
in this model (129). Interestingly, a decreased expression of sero-
tonin receptors (5 HT-R) is observed in the amygdala and dorsal
raphe of ghsr−/−mice (119). Although ghrelin−/−mice have lower
anxiety in basal unstressed conditions in three different behavioral
tests (open field, EPM, light/dark box), they are also more anxious
in response to acute restraint stress and show exacerbated central
responses to stress as well (130). This stress response involves, not
only the hypothalamus and amygdala, but also urocortin 1 neu-
rons in the Edinger-Westphal nucleus. Interestingly, exogenous
ghrelin reverses the exacerbated neuronal activation in the hypo-
thalamic PVN and medial nucleus of the amygdala in ghrelin−/−
mice after acute restraint stress, supporting an anxiolytic action of
ghrelin (130). The differential response in basal and in stress con-
ditions suggests that the role of the ghrelin system may be different
depending on the context. Ghrelin may also prevent excessive anx-
iety under conditions of chronic stress (see next paragraph for
animal models of chronic social defeat stress). Indeed, ghsr−/−
mice display enhanced deleterious effects of chronic exposure to
stress. Interestingly, increased plasma ghrelin levels induced by
caloric restriction also produces anxiolytic and anti-depressant-
like effects (40). Thus, stress-induced elevated ghrelin may help to
control excessive anxiety and prevent depression in conditions of
chronic stress exposure (Figure 3).
Finally, administration of antisense DNA for ghrelin into the
lateral ventricle induces anxiolytic and antidepressant responses
in the forced-swim test, EPM as well as in the black and white
test and conditioned fear test in rats (131), which is in favor of an
anxiogenic role of endogenous ghrelin.
REGULATION OF PREPROGHRELIN-DERIVED PEPTIDES IN ANIMAL AND
HUMAN PATHOPHYSIOLOGY
Animal pathophysiology
Several studies suggest that ghrelin plays an important role in
metabolic adaptations following chronic stress, which function
would be to defend against depressive-like symptoms of chronic
stress but which can also lead to metabolic dysfunctions in the
long-term.
Animal models of anxiety/depression can be induced by
chronic exposure to social stress (CSDS), a model of prolonged
psychosocial stress in humans. CSDS is based on a resident
intruder paradigm in which a test mouse is introduced into the
cage of an aggressive CD1 mouse for a few minutes each day dur-
ing several days and is a model of prolonged social defeat stress in
rodents. Acylated ghrelin levels are increased in CSDS mice (40)
(Table 1). Elevated ghrelin levels induced by chronic exposure
to social stress are associated with increased caloric intake and
body weight gain in male C57BL/6 mice and minimizes CSDS-
associated depression-like behavior whereas stressed mice lacking
ghrelin receptors (ghsr−/−mice) or treated i.c.v with ghrelin recep-
tor antagonist [d-Lys3]-GHRP-6 show attenuated weight gain and
feeding responses under the same social stress paradigm (41, 132).
In high-anxiety Wistar Kyoto rats, lower total ghrelin levels com-
pared to SD low-anxiety rats in both fasted and fed states were
reported (42). In rats, exposure to water avoidance stress, an acute
psychological stress, mobilizes total ghrelin. Interestingly, higher
plasma ghrelin levels are induced after stress in low-anxiety SD
rats than in high-anxiety Wistar Kyoto rats (133), suggesting that
animals with low anxiety have a greater ability to mobilize ghrelin
in response to stress.
Human pathophysiology
Anxiety/stress. Although stress elevates plasma ghrelin levels in
animal models, which was proposed by some studies to increase
emotional eating and help defend against some depressive symp-
toms induced by stress, there are farther less evidence in human
pathophysiology that ghrelin is involved in the eating/metabolic
response to stress (Figure 2).
Psychological stress, induced by public speaking over 2 days,
does not modify plasma total ghrelin levels (60). In another
study performed in normal weight, obese patients and sub-
jects with binge-eating, social stress test does not modify ghrelin
levels. However, when subjects are analyzed according to their
cortisol response, ghrelin levels are found increased in corti-
sol responders subjects following the stress whereas no change
occurred in cortisol non-responders and positive correlations
are found between ghrelin and cortisol change (76). In emo-
tional eaters, evaluated by the “emotional eating subscale of the
Dutch eating behaviors questionnaire,” anticipation of a psy-
chological stressor (public speaking) leads to a greater food
consumption than in-non-emotional eaters and ghrelin levels
are more elevated in women anticipating the stressor com-
pared to those not subjected to the stressor. Interestingly, the
normal decline in ghrelin concentrations following food con-
sumption is lower in non-emotional eaters (77), suggesting that
ghrelin may contribute to emotional eating following a stressor
(Figure 3).
Depression. In the majority of studies, no difference in plasma
total or acylated ghrelin levels were reported between patients with
major-depressive disorder (MDD) and healthy subjects (Figure 2;
Table 2) (78–81). However, in MMD patients, ghrelin levels
correlate positively with the severity of reduced appetite and
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negatively with gray matter volume of the VTA (81), and correlate
with eating behavior scales like the three-factor eating question-
naire (TFEQ), suggesting that ghrelin may be associated with
increased susceptibility to eating disorders observed in psychiatric
patients (78).
Whether ghrelin can contribute to the degree of depression
is not clearly demonstrated. In women across the weight spec-
trum, there was no relationship between ghrelin and symptoms
of depression or anxiety (82). Interestingly, however, plasma acyl
ghrelin levels were higher in treatment-resistant patients than
responsive patients or in controls (83). One bias of these studies is
that some of them do not discriminate ghrelin levels according to
patients with or without medication (either neuroleptics, anti-
depressant, antipsychotics or hypnotics). However, treatments
impact plasma ghrelin levels and metabolic modifications may
be secondary to the treatment. For example, in one study with
MDD patients, treatment reduced plasma levels of acyl and desacyl
ghrelin, as well as BMI, and ghrelin levels were lower than in con-
trols (84). In contrast, treatment of lean patients with MDD with
maprotiline, an anti-depressant, resulted in a minor increase in
total ghrelin levels and WG (85). In both major-depressive episode
(MDE) and bipolar disorder manic episode (BD-me), acylated
ghrelin levels are decreased by electroconvulsive therapy (ECT),
although BMI is unchanged (86), but remains higher than in
controls.
Schizophrenia. Weight gain is a common side effect of the
atypical antipsychotics (AAPs) used to treat schizophrenia and
it has been related with the orexigenic effect of elevated serum
ghrelin rather than leptin deficit (134). Among five widely used
AAPs (clozapine, olanzapine, risperidone, amisulpride, or queti-
apine), only the later did not elevate the ghrelin level. Ghrelin
gene polymorphisms have been associated with pathogenic vari-
ations in plasma lipid concentrations, blood pressure, plasma
glucose, and BMI. Four SNPs (Leu72Met, −501A/C, −604 G/A,
and −1062 G>C) were genotyped in 634 schizophrenia patients
and 606 control Chinese Han subjects (135). These four GHRL
gene SNPs were not associated with SZ in this Chinese Han
population. However, the −604 G/A polymorphism was asso-
ciated with significant BW and BMI increases during AAP
treatment.
The effect of a 16 week-treatment with olanzapine was studied
by functional magnetic resonance imaging in conjunction with
a task requiring visual processing of appetitive stimuli in schiz-
ophrenic patients and healthy controls (136). Neuronal activity
in the fusiform gyrus was brought back to “normal” after olan-
zapine treatment and this change was positively correlated with
the restoration in ghrelin and leptin levels, following the treat-
ment. However, others have reported that serum leptin levels
might be a more sensitive biomarker than ghrelin or adiponectin
levels to differentiate schizophrenic patients and healthy controls
(137).
In some of the cited disorders, we need to be precautious with
the interpretation because they concern small groups of subjects
and inter-individual variability in the ghrelin pattern has to be
considered (Table 2).
GHRELIN-GH AXIS AND PSYCHIATRIC DISORDERS
As ghrelin has initially been described as a powerful GH secre-
tagogue and a number of studies have focused on its role as a
regulator of the GH/IGF-1 axis (1, 13, 138), the link between ghre-
lin, GH axis, and psychiatric disorders needs to be questioned.
The GH/IGF-1 axis is deregulated in anorexia nervosa and the
evolution of GH levels during renutrition is predictive of short-
term outcome in AN-R patients (139, 140). More specifically, low
GH levels at admission and absence of GH reduction after weight
recovery could be predictive of short-term relapse. In patients with
depression or post-traumatic stress disorder (PTSD), sleep-related
GH secretion is lower compared to healthy controls (141). Abnor-
mal IGF-1 levels have also been reported in several psychiatric
disorders like schizophrenia and major depression (142). Inter-
estingly, in GH-deficient patients symptoms of depression and
cognitive impairments are improved after GH therapy (143).
Several components of the GH/IGF-1 axis also modulate
anxiety and depression. At the hypothalamic level, GH secre-
tion is directly regulated by two antagonistic neurohormones:
GHRH stimulates whereas somatostatin inhibits GH secretion.
Intracerebroventricular and intra-amygdala administrations of
somatostatin induces anxiolytic and anti-depressant effects in
rats (144, 145) while somatostatin KO mice show hyperactivity
and anxiety-like behavior (146). GHRH KO mice display anxiety
and depression-related behaviors (147). In addition, the GHRH
agonist, JI-34, induces anxiety and depression (148) whereas the
GHRH antagonist, MZ-4-71, elicits anxiolytic and anti-depressant
effects (149).
Interestingly, deficiency in circulating and hippocampal IGF-1
induced by virus-mediated IGF-1 KO is associated with depres-
sive symptoms measured in the forced-swim test in mice (150).
A recent study brings an interesting point of view on the link
between ghrelin–GH axis and stress-associated mental diseases. In
a rodent model of PTSD, in which rats are repeatedly exposed to a
stressor and display enhanced fear, stress-related increases in cir-
culating ghrelin are necessary and sufficient for stress-associated
vulnerability to exacerbated fear learning. These actions of ghre-
lin require GH in the amygdala to exert fear-enhancing effects,
suggesting that ghrelin–GH axis can mediate maladaptive changes
following prolonged stress (151).
CONCLUSION
Ghrelin interacts with the GHS-R to modulate GH secretion, nat-
ural and artificial reward as well as stress and anxiety. Anhedonic
symptoms, which include loss of pleasure, appetite, and moti-
vation, are often observed in these disorders in association with
altered ghrelin secretion and/or signaling. Whether dysfunction of
the ghrelin/GHS-R signal contributes to the mechanism respon-
sible for the development of the disease or can help to minimize
some symptoms associated with these psychiatric disorders is still
debated.
The recent demonstration of the heterodimerization of the
GHS-R and the dopamine D2-receptor requested for appetite
regulation in animal is a novel avenue for future studies deci-
phering the role of ghrelin in reward and addictions that are both
impaired in psychiatric disorders. The multiple links between the
Frontiers in Endocrinology | Neuroendocrine Science October 2014 | Volume 5 | Article 163 | 14
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Labarthe et al. Ghrelin and psychiatric disorders
ghrelin/GHS-R system and other biological pathways, via the func-
tional heterodimerization with other receptors that could play a
role in psychiatric disorders, would be interesting to explore.
Finally, although ghrelin has been proposed to be a pharma-
cological target for treatment of psychiatric disorders, only a few
data on the involvement of the other ghrelin-derived peptides,
DAG, and obestatin, in psychiatric disorders are available. This
would require further investigations.
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